abs430.txt	background		buparlisib	is	an	oral	pan-class	i	phosphotidyinositol-3-kinase	(pi3k)inhibitor	the	present	phase	study	evaluated	safety	pharmacokinetics	andefficacy	of	with	capecitabine	in	patients	metastatic	breastcancer	and	methods	received	once	daily	(range	50	to	100mg)	for	3	weeks	twice	1000	1250	mg/m2)	2weeks	a	1-week	break	dose	escalation	used	traditional	+	design	withstandard	definitions	dose-limiting	toxicity	(dlt)	maximum	tolerated	results	25	enrolled	23	were	evaluable	dlt	17	wereevaluable	response	combination	wasbuparlisib	100	mg	mg/m2	dlts	includedgrade	hyperglycemia	grade	confusion	most	common	toxicitieswere	diarrhea	elevation	aspartate	aminotransferase	alaninetransaminase	one	patient	exhibited	complete	treatment	four	hada	confirmed	partial	cohorts	4	which	doseremained	constant	but	was	increased	significant	increasesin	plasma	concentration	noted	conclusion	withmetastatic	breast	cancer	generally	well-tolerated	several	patientsdemonstrating	prolonged	responses	unexpectedly	low	rates	pik3ca	mutations	(3of	17)	seen	only	2	7	tumors	subtyping	luminal	makingexploration	these	putative	predictive	markers	impossible	further	thecombination	not	unreasonable	expanded	sequencinganalysis	better	elucidate	potential	drug-drug	interactions	more	accuratepredictive	biomarkers
